Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
General Internal Medicine
•
Rheumatology
•
Vasculitis
How would you approach EGPA with renal involvement that was on maintenance Rituximab, last infusion two months ago and develops new onset liver involvement?
Other causes if liver disease excluded.
Related Questions
What is your experience of using rituximab for GPA with renal involvement following a recent myocardial infarction?
Do you extend the duration of maintenance therapy past 24 months for patients with ANCA glomerulonephritis who have multiple organ involvement?
How would you approach management of a patient with classic GCA symptoms, elevated ESR and improvement with steroids, but negative temporal artery biopsy and CTA imaging without evidence of vasculitis?
How would you manage a patient on tocilizumab for recently diagnosed severe GCA who developed a bowel obstruction several weeks after the first dose of Tocilizumab?
Do you avoid tocilizumab in patients with prior bariatric surgery given the risk of GI perforation?
Are there patients with granulomatosis with polyangiitis on maintenance rituximab therapy for whom you do not co-administer glucocorticoid therapy?
How would you interpret the presence of both high titer anti-PR3 and anti-MPO antibodies in a pANCA positive patient with evidence of small vessel vasculitis?
How do you treat IgA cutaneous vasculitis with retiform purpura and evidence of fibrinoid necrosis on skin biopsy?
Are you aware of drug induced-ANCA vasculitis associated with new wt loss medications (ex tirzepatide or semaglutide?
How do you approach the management of aortitis in patients with ANCA-associated vasculitis?